Annual EBIT
-$93.65 M
+$37.72 M+28.71%
31 December 2023
Summary:
Protagonist Therapeutics annual earnings before interest & taxes is currently -$93.65 million, with the most recent change of +$37.72 million (+28.71%) on 31 December 2023. During the last 3 years, it has fallen by -$29.41 million (-45.77%). PTGX annual EBIT is now -904.96% below its all-time high of -$9.06 million.PTGX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$41.45 M
-$2.66 M-6.86%
30 September 2024
Summary:
Protagonist Therapeutics quarterly earnings before interest & taxes is currently -$41.45 million, with the most recent change of -$2.66 million (-6.86%) on 30 September 2024. Over the past year, it has dropped by -$3.13 million (-8.16%). PTGX quarterly EBIT is now -120.09% below its all-time high of $206.31 million, reached on 31 March 2024.PTGX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
$149.11 M
-$3.13 M-2.05%
30 September 2024
Summary:
Protagonist Therapeutics TTM earnings before interest & taxes is currently $149.11 million, with the most recent change of -$3.13 million (-2.05%) on 30 September 2024. Over the past year, it has increased by +$302.33 million (+197.32%). PTGX TTM EBIT is now -2.05% below its all-time high of $152.24 million, reached on 30 June 2024.PTGX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PTGX EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +28.7% | -8.2% | +197.3% |
| 3 y3 years | -45.8% | -22.2% | +238.6% |
| 5 y5 years | -135.8% | -151.1% | +301.2% |
PTGX EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -45.8% | +28.7% | -120.1% | +2.1% | -2.0% | +197.3% |
| 5 y | 5 years | -135.8% | +28.7% | -120.1% | +2.1% | -2.0% | +197.3% |
| alltime | all time | -905.0% | +28.7% | -120.1% | +2.1% | -2.0% | +197.3% |
Protagonist Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$41.45 M(+6.9%) | $149.11 M(-2.1%) |
| June 2024 | - | -$38.79 M(-118.8%) | $152.24 M(+2.4%) |
| Mar 2024 | - | $206.31 M(+795.1%) | $148.68 M(-258.8%) |
| Dec 2023 | -$93.65 M(-28.7%) | $23.05 M(-160.1%) | -$93.65 M(-38.9%) |
| Sept 2023 | - | -$38.33 M(-9.5%) | -$153.22 M(+4.1%) |
| June 2023 | - | -$42.35 M(+17.6%) | -$147.19 M(+0.6%) |
| Mar 2023 | - | -$36.02 M(-1.4%) | -$146.28 M(+11.3%) |
| Dec 2022 | -$131.37 M(+4.4%) | -$36.52 M(+13.0%) | -$131.37 M(-0.4%) |
| Sept 2022 | - | -$32.30 M(-22.1%) | -$131.87 M(-1.2%) |
| June 2022 | - | -$41.44 M(+96.3%) | -$133.50 M(+8.6%) |
| Mar 2022 | - | -$21.11 M(-43.0%) | -$122.94 M(-2.3%) |
| Dec 2021 | -$125.84 M(+95.9%) | -$37.02 M(+9.1%) | -$125.84 M(+17.0%) |
| Sept 2021 | - | -$33.93 M(+9.9%) | -$107.59 M(+32.2%) |
| June 2021 | - | -$30.88 M(+28.6%) | -$81.41 M(+18.7%) |
| Mar 2021 | - | -$24.02 M(+28.1%) | -$68.61 M(+6.8%) |
| Dec 2020 | -$64.25 M(-17.3%) | -$18.76 M(+142.2%) | -$64.25 M(+3.7%) |
| Sept 2020 | - | -$7.74 M(-57.2%) | -$61.96 M(-12.4%) |
| June 2020 | - | -$18.08 M(-8.0%) | -$70.73 M(-15.2%) |
| Mar 2020 | - | -$19.66 M(+19.3%) | -$83.45 M(+7.4%) |
| Dec 2019 | -$77.71 M | -$16.48 M(-0.2%) | -$77.71 M(+4.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | -$16.51 M(-46.4%) | -$74.10 M(+10.6%) |
| June 2019 | - | -$30.80 M(+121.3%) | -$66.98 M(+47.5%) |
| Mar 2019 | - | -$13.92 M(+8.2%) | -$45.41 M(+14.3%) |
| Dec 2018 | -$39.72 M(+7.5%) | -$12.87 M(+37.0%) | -$39.72 M(+35.0%) |
| Sept 2018 | - | -$9.39 M(+1.6%) | -$29.43 M(+17.6%) |
| June 2018 | - | -$9.24 M(+12.3%) | -$25.02 M(-19.1%) |
| Mar 2018 | - | -$8.23 M(+219.8%) | -$30.91 M(-16.4%) |
| Dec 2017 | -$36.96 M(+13.1%) | -$2.57 M(-48.3%) | -$36.96 M(-19.3%) |
| Sept 2017 | - | -$4.98 M(-67.1%) | -$45.78 M(-4.5%) |
| June 2017 | - | -$15.13 M(+6.0%) | -$47.94 M(+20.2%) |
| Mar 2017 | - | -$14.27 M(+25.2%) | -$39.90 M(+22.1%) |
| Dec 2016 | -$32.67 M(+120.8%) | -$11.40 M(+59.7%) | -$32.67 M(+24.3%) |
| Sept 2016 | - | -$7.14 M(+0.7%) | -$26.27 M(+13.5%) |
| June 2016 | - | -$7.09 M(+0.7%) | -$23.15 M(+20.9%) |
| Mar 2016 | - | -$7.04 M(+40.8%) | -$19.14 M(+29.4%) |
| Dec 2015 | -$14.79 M(+58.8%) | -$5.00 M(+24.4%) | -$14.79 M(+51.1%) |
| Sept 2015 | - | -$4.02 M(+30.4%) | -$9.79 M(+69.7%) |
| June 2015 | - | -$3.08 M(+14.7%) | -$5.77 M(+114.7%) |
| Mar 2015 | - | -$2.69 M | -$2.69 M |
| Dec 2014 | -$9.32 M | - | - |
FAQ
- What is Protagonist Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Protagonist Therapeutics?
- What is Protagonist Therapeutics annual EBIT year-on-year change?
- What is Protagonist Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly EBIT year-on-year change?
- What is Protagonist Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Protagonist Therapeutics?
- What is Protagonist Therapeutics TTM EBIT year-on-year change?
What is Protagonist Therapeutics annual earnings before interest & taxes?
The current annual EBIT of PTGX is -$93.65 M
What is the all time high annual EBIT for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual earnings before interest & taxes is -$9.06 M
What is Protagonist Therapeutics annual EBIT year-on-year change?
Over the past year, PTGX annual earnings before interest & taxes has changed by +$37.72 M (+28.71%)
What is Protagonist Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of PTGX is -$41.45 M
What is the all time high quarterly EBIT for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly earnings before interest & taxes is $206.31 M
What is Protagonist Therapeutics quarterly EBIT year-on-year change?
Over the past year, PTGX quarterly earnings before interest & taxes has changed by -$3.13 M (-8.16%)
What is Protagonist Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of PTGX is $149.11 M
What is the all time high TTM EBIT for Protagonist Therapeutics?
Protagonist Therapeutics all-time high TTM earnings before interest & taxes is $152.24 M
What is Protagonist Therapeutics TTM EBIT year-on-year change?
Over the past year, PTGX TTM earnings before interest & taxes has changed by +$302.33 M (+197.32%)